Sign up to save your podcasts
Or
Share Recently Approved Drugs: Durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC)
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Recently Approved Drugs: Durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC)
Rami Manochakian, M.D., a thoracic clinical oncologist at the Mayo Clinic in Florida, presents information on the recently approved drug in oncology, durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC) after the completion of radiation therapy.
View all episodes
By American Society of Clinical Oncology (ASCO)
4.5
3131 ratings
Rami Manochakian, M.D., a thoracic clinical oncologist at the Mayo Clinic in Florida, presents information on the recently approved drug in oncology, durvalumab for patients with stage III Non-Small Cell Lung Cancers (NSCLC) after the completion of radiation therapy.
More shows like ASCO Education
View all
Exchanges
978 Listeners
NEJM This Week
320 Listeners
JAMA Clinical Reviews
497 Listeners
Journal of Clinical Oncology (JCO) Podcast
40 Listeners
JCO Oncology Practice Podcast
18 Listeners
ASCO Daily News
57 Listeners
GeriPal - A Geriatrics and Palliative Medicine Podcast
283 Listeners
The Curbsiders Internal Medicine Podcast
3,342 Listeners
WSJ Minute Briefing
677 Listeners
Core IM | Internal Medicine Podcast
1,153 Listeners
ASCO Guidelines
44 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
365 Listeners
NEJM AI Grand Rounds
58 Listeners
Two Onc Docs
188 Listeners
Oncology Brothers: Practice-Changing Cancer Discussions
43 Listeners